When will we know the new district and territory footprints? I know some in my pod won't stay if there are overnights. What is sad is that thiis person will be the one that is kept and then they will find another job as soon as possible leaving the rest of us in the cold. I'm hoping they'll announce the new territories so that those people who don't want them will start looking now for a new position and let the people who want to stay have a better chance!
-
General DiscussionCP Bulletin Important: Board Posting Policies Ask the Webmaster The Darkened Sample Closet Latest CP Job Ratings Ask a Whistleblower Attorney Employment Harassment & Discrimination Forum Healthcare Reform Discussions Haiku, etc. Am I Overreacting? Cafepharma Playground In the Pipe Political Discussions The Politics of Healthcare Financial Forum How do I... Tricks of the Trade Industry Veterans Industry Veterans - registered posting only
Tell Me About Your Company Industry Rumors Hidden Jobs Job-Seekers Dealing with Your Manager MSL Board -
Pharma/BiotechPharma/Biotech Comp - Gen Discussion |Pharma Sales Pharma and COVID-19 Pharma/Biotech Companies - Virtual/Inside Sales AI in Pharma/Biotech Pharma/Biotech Companies - Job Openings Pharma/Biotech Companies - Compliance Pharma/Biotech Companies - Managed Care and Reimbu Pharma/Biotech Companies - In the News Pharma/Biotech Companies - Stock Discussions Biotech Startups Abbott Abbott Nutrition AbbVie Latest AbbVie news
Acadia Pharmaceuticals Acorda Therapeutics Acrotech Biopharma Actelion ADMA Biologics AEterna Zentaris Agios Pharmaceuticals Aimmune Akebia Alcami Alcon Alcresta Alexion Alimera Sciences Alkermes Allegis Pharmaceuticals Allergan Alnylam Pharmaceuticals Amarin Amgen Amplity Amylx Apellis Apotex Aqua Pharmaceuticals Archimedes Pharma Arcutis Ardelyx Argenx ARS Pharma Arvinas Ascend Therapeutics Ascendis Ashfield Healthcare Astellas AstraZeneca AstraZeneca news
Atley Pharmaceuticals Autolus Therapeutics Avidas Pharmaceuticals AVEO Oncology Avion Pharmaceuticals Axsome Therapeutics AYTU BioPharma Azurity Pharmaceuticals Basilea Bausch & Lomb Baxter Bayer Biocodex Biocon Biologics Biofrontera Biogen Biohaven Boehringer Ingelheim Braeburn Pharmaceuticals Braintree Laboratories Bristol-Myers Squibb Cadence Pharmaceuticals Camber Pharmaceuticals Camurus Cangene BioPharma Caswood Catalyst Pharmaceuticals Celgene Cell Therapeutics Celltrion USA Centocor Ortho Biotech Centrix Pharmaceuticals Cephalon Chelsea Therapeutics Chiesi USA Chiron Circassia Pharmaceuticals Clarus Therapeutics Clinical Data Clovis Oncology Coherus BioSciences CollaGenex Collegium Pharmaceutical Columbia Labs Commonwealth Pharma Compass Therapeutics Cord Blood Registries Corium Covidien Crinetics Pharmaceuticals Critical Therapeutics CSL Behring Cubist Cumberland Pharmaceuticals Currax Pharmaceuticals CV Therapeutics Cycle Pharmaceuticals Cypress Bioscience Daiichi-Sankyo DARA BioSciences Dendreon Depomed Dermavant Dermik Laboratories Dermira Dey Discovery Labs Durata Therapeutics Dynavax ECR Pharmaceuticals Edwards Pharmaceuticals Egalet Eisai EKR Therapeutics Elan Eli Lilly Latest Lilly News
Emergent Biosolutions Endo Enzon Esperion EUSA Pharma Exaeris Exelixis Exeltis Eyetech Pharmaceuticals Ferndale Labs Ferring Forest Laboratories FSC Pediatrics Galderma Genentech Gensco Laboratories Genta Genzyme Gilead Sciences Gilead Sciences news
GlaxoSmithKline Graceway Greenwich Biosciences Greer Grifols USA GTX Halozyme Therapeutics Hawthorn Pharmaceuticals HCP Concierge Heron Therapeutics Horizon Pharma Hospira Human Genome Sciences ImClone IM HealthScience ImmunityBio Immunocore Impax Labs/Global Incline Therapeutics Incyte Indivior Innovex Insmed Insys Therapeutics Intarcia Therapeutics Intercept Pharma InterMune Intrabio Intra-Cellular Therapies Inventiva Ionis Pharmaceuticals Ipsen IQVIA Sales Iroko Ironshore Pharmaceuticals Ironwood Pharmaceuticals Ista Pharma Janssen Jazz Pharmaceuticals JDS Pharmaceuticals Johnson & Johnson latest J&J news
Jounce Therapeutics Journey Medical Corp Kadmon Pharmaceuticals Kala Pharmaceuticals Kaleo Pharma Kedrion Kenuve Keryx Biopharmaceuticals Kite Pharma Kowa Pharmaceuticals Kyowa Kirin Lannett Leo Pharmaceuticals Lexicon Pharmaceuticals Ligand L'Oreal Dermatology Luitpold Pharmaceuticals Lundbeck Lupin Madrigal Pharmaceuticals MannKind Mallinckrodt Marinus Mayne Pharma MCR American Pharmaceuticals Mead Johnson Nutritionals Meda Medicines360 Medicis MedImmune Medivation Medix Melinta Therapeutics Merck Merrimack Pharma Merz Pharmaceuticals Metagenics Middlebrook Pharmaceuticals Millennium/Takeda Oncology Company Mission Pharmacal Mitsubishi Tanabe Pharma Moderna Therapeutics Morphosys Myriad Pharmaceuticals Nephron Pharmaceuticals Nestle Health Science Nestle Pediatric Nutrition Neurelis Neurocrine NeurogesX New Haven Pharmaceuticals NexMed Nitromed Novaquest Novartis Novavax Noven Pharmaceuticals Novo Nordisk NPS Pharmaceuticals Nuerex Pharmaceuticals Numedica Nycomed Octapharma Odyssey On Call ONY Inc. Onyx Pharmaceuticals Optimer Pharmaceuticals Optinose Orapharma Orexigen Therapeutics Orexo Organon Ortho Biotech Oscient Pharmaceuticals Osiris Otonomy Otsuka Oyster Point Pharma Pacira Pan American Laboratories PamLabs LLC Par Paratek Par Sterile Products PDI Dedicated PDI Shared PDL Biopharma Peregrine Pharmaceuticals Pernix Perrigo Pharmaceuticals Pfizer Latest Pfizer news
Pfizer Consumer Healthcare Pharmacyclics Phathom Pharmaceuticals Pinnacle Biologics Poly Pharmaceuticals Procter & Gamble Prollenium Medical Prometheus Labs Promius Pharma ProPharma Sales PruGen Puma Biotechnology Purdue Questcor Radius Health Ranbaxy Reckitt Benckiser Regeneron Relypsa Revance Biotech Rion Health Ritedose Roche Romark RVL Pharmaceuticals Sage Therapeutics SagePath Medical Salix Sandoz Sanofi Santarus Savient Scilex Pharmaceuticals Seattle Genetics Sebela Pharmaceuticals Seqirus Serono Servier Shionogi Shire Sirion Therapeutics SkinMedica Slate Pharma Sobi Solstice Neurosciences Solvay Somaxon Spectrum Pharmaceuticals Sprout Pharmaceuticals Stiefel Labs Strongbridge Biopharma Stratus Pharmaceuticals Sucampo Summit Therapeutics Sun Pharma Sunesis Pharmaceuticals Sunovion Supernus Syneos Health Synthon Taiho Oncology Takeda Talecris Biotherapeutics Taro Pharmaceuticals Tarsus Pharmaceuticals TEAMM Pharmaceuticals Telesta Therapeutics Telix Pharmaceuticals Tesaro Teva Neuroscience Teva Oncology Teva Respiratory Teva Women's Health Thea Pharma TherapeuticsMD TherRx Thrombogenics Titan Pharmaceuticals Travere Therapeutics Tris Pharma UCB Pharma Ultragenyx United Therapeutics Upsher Smith Labs US WorldMeds Valeant Pharmaceuticals Valera Pharmaceuticals Vanda Pharmaceuticals Vanguard Pharma VaxInnate Veloxis Pharmaceuticals Vericel Vertex Vertical Pharmaceuticals Veru Pharma Verus Pharmaceuticals VI Aesthetics Viatris ViroPharma Vivus Pharmaceuticals Warner Chilcott Watson Wraser Pharmaceuticals Xanodyne Xenoport Pharmaceuticals Xeris Pharma Xymogen Zealand Pharma Zogenix ZS Pharma Zylera Pharma Zymogenetics -
Lab/DiagnosticsLaboratory/Diagnostic Sales General Discussion Lab/Diagnostics and COVID-19 Laboratory/Diagnostic Sales - Managed Care and Rei Acupath Labs Accurate Diagnostic Labs Aegis Sciences Corporation Akers Biosciences AIT Laboratories Alliance Imaging American Pathology Partners Ameripath Ameritox Ammon Labs Aperio Ariosa ASPiRA Labs Atherotech Aureon Labs Aurora Diagnostics AVEE BillionToOne Bio Reference Blood Centers of Wisconsin Blue Earth Diagnostics Bostwick Laboratories Calloway Laboratories Caris Life Sciences Castle Medical Labs CBL Clarient Cordant Health Solutions CPL CSI Laboratories Cylex Cytyc Dermpath Diagnostic Imaging Companies Digene Dominion Diagnostics Empire City Labs Enzo Laboratories Eurofins Exact Sciences Exosome Diagnostics Fellow Foundation Medicine Genomic Health Genoptix Genova Diagnostics GI Path Guardant Health Hunter Labs Insight Health Interpace Diagnostics Interpath Laboratory Invitae Know Error Labcorp LabSource Leica Liposcience Lucid Diagnostics Manhattan Labs MedComp Sciences Medical Diagnostic Laboratories (MDL) Millennium Laboratories MobilexUSA Miraca Life Sciences Myriad Genetics NanoString NantWorks Natera Neogenomics Omnyx Oncoplex Diagnostics OPKO Health OPKO Renal Ovagene Oncology Oxford Immunotec PAML/Paclab PathGroup Pathline Labs Pathnostics Pathway Genomics Phenogen Sciences Philips Pathology Phosphorus Diagnostics Physicians Choice Laboratory Services Plus Diagnostics Polymedco Predictive Biosciences Precision Therapeutics Progenity Proove Biosciences QDx Pathology Quest Diagnostics Quidel Renaissance Rx Sequenom Shiel Solstas Lab Partners SOPHiA Genetics StrataDX Summit Diagnostics Synergy Laboratories Theranos Labs Thermo Fisher Scientific Tri-path True Health Diagnostics United Allergy Services Ventana Medical Systems Veractye VWR International
-
Animal HealthAbbott Animal Health Antech Diagnostics Arthrex Vet Systems Bayer Animal Health Boehringer Ingelheim Vetmedica Butler CEVA Columbus Serum Covetrus DVM Resources Elanco Idexx labs Intervet Merial Midwest MWI Novartis Animal Health Parnell Veterinary Pharmaceuticals Patterson Veterinary Pegasus Laboratories Penn Vet Pfizer Animal Health Schering Plough Animal Health Veterinary Imaging Companies Veterinary Rx Diets Virbac Zoetis
-
Medical Equipment/DeviceMedical Equipment/Device Sales-General Discussion Med Device and COVID-19 Medical Equipment/Device Sales - Compliance Medical Equipment/Device Sales - Credentialing Medical Equipment/Device Sales - In the News Medical Equipment/Device - Stock Discussions AADCO Medical Abbott Device Abbott Vascular Abiomed Acclarent ACell Acumed Aerocrine All Star Oxygen Alvimedica Ambu American Medical Systems AngioDynamics Applied Medical Apria Apyx Medical Aragon Surgical Arjohuntleigh Arthrex Arthrotek Orthopedics Ascensia Diabetes Care Atrium Medical Augusta Medical Systems Avinger Axogen Becton Dickinson Biomet Orthopedics Biotronik Bioventus Blue Belt Technologies Boston Scientific Bracco Diagnostics Brainlab BSN Medical B. Braun Medical Caldera Medical Canfield Imaging Systems Cardionet Cardiovascular Systems Cardiva Medical CareFusion Coapt Systems Coloplast Conceptus ConforMIS Conmed Contract Manufacturer Reps ConvaTec Cook Cooper Surgical Corza Medical Covidien CR Bard CryoLife CSI Cutera Cyberonics Cytyc Surgical Products Daniels Sharpsmart Depuy Mitek DePuy Ortho DeRoyal Dexcom DJ Orthopedics Dornier Dynasplint Edwards Life Sciences Encision EndoChoice Endogastric Solutions Entellus Medical ERMI Ethicon Device Exactech Orthopedics Fidia Fresenius Medical Gambro GE Healthcare General Medical Sales [moved to new board at top o Genzyme Globus Medical GN ReSound Gore Medical Greiner Bio-One Gyrus Guided Therapeutics Haemonetics Halyard Health Hanger Healthtronics Healthpoint Medical Hill-Rom Histogenics Hollister Hologic Idev Technologies IMRIS Inari Medical Independent Medical Contractors Integra Life Sciences Intuitive Surgical Intuitive Surgical Patient Discussions
iRhythm Karl Storz KCI Kimberly-Clark KLS Martin Laborie LDR Medical LeMaitre Vascular LifeCell Lifewatch Lincare Linvatec Magnolia Medical Technologies MAKO Surgical Mammotome Maquet Medical Systems Masimo Mazor Robotics McGhan Medacta Medartis Medela Mederi Therapeutics The Medicines Company Medafor Medline Medtronic Mentor Mercury Medical Merit Medical Microline Surgical/Starion Instruments MicroPort Orthopedics Mimedx Mimic Technologies Mindray Minerva Surgical Molnlycke Mpathy Medical Natus Medical Neomend Neotract NeuroMetrix Neurotron Neurowave Medical Technologies Nevro Nexus Spine Norgenix Novadaq Novasys Medical NuVasive Oceana Therapeutics Olympus Olympus Endoscopy Organogenesis Orthofix OsteoMed Oticon Otto Bock Owens & Minor Pacific Pulmonary Services Paragon 28 Penumbra Philips Healthcare Phonak Plus Orthopedics PolyNovo Preferred Homecare Procept BioRobotics Q-Med Regenesis Biomedical Richard Wolf Medical Rotech RS Medical Salient Surgical SCA Americas Sciton Sensus Healthcare Siemens Healthcare Sicel Technologies Sivantos Small Bone Innovations Smith & Nephew Smiths Medical Solta Medical Solventum Sonosite Sorin Spiracur Stamen Medical Systems Starkey Hearing Technologies Starplex Scientific St Jude Medical Stryker SuperCare Surgiquest Synthes Systagenix Wound Care TARIS Biomedical TEI Biosciences Teleflex Medical Terumo Medical Corporation Thornhill Research Tornier TransEnterix Treace Medical Tri-anim Ulthera ULURU, Inc. Universal Hospital Services Uromedica Uroplasty US Endoscopy Vascular Solutions Vein Clinics of America Verathon Verichip Vision Sciences Vital Signs VNUS Technologies Vyaire Welch Allyn Widex Wright Medical Zeltiq Zimmer Zoll Medical
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an alternative browser.
You should upgrade or use an alternative browser.
Anonymous
Guest
Anonymous
Guest
When will we know the new district and territory footprints? I know some in my pod won't stay if there are overnights. What is sad is that thiis person will be the one that is kept and then they will find another job as soon as possible leaving the rest of us in the cold. I'm hoping they'll announce the new territories so that those people who don't want them will start looking now for a new position and let the people who want to stay have a better chance!
Are you insane? Whats wrong with you. You may be getting the ax with the rest of the 60%. How arrogant and naive you are. How old are you? 20 something, blond, and female. OMG. Do you really think that they will not be cutting again. Do you think that everyone getting cut wants to look for a new job. Hell no because there are no jobs out there. Yes, pharmaceuticals is not the job it used to be and the industry is going to hell in a hand basket. However, nobody wants to leave especially the ones that have over 10 years with the company or are in their late 40s and 50s. You bet they will be cutting again and rumor is in the fall. Nobody is safe especially the 40% that survive because the overall plan is to eliminate another 65% so if you have 800-900 reps left Novartis will have about around 400 by 2013. Words of advice to you my little naive friend. Novartis does not care about you and they only see you as a number. Grow up and start looking for another job or go back to school and get a real degree. I bet your degree is in fashion design. They will not announce anything because there is no set territory and never will be. They are called temporary territories and will never be safe.
Anonymous
Guest
Anonymous
Guest
Are you insane? Whats wrong with you. You may be getting the ax with the rest of the 60%. How arrogant and naive you are. How old are you? 20 something, blond, and female. OMG. Do you really think that they will not be cutting again. Do you think that everyone getting cut wants to look for a new job. Hell no because there are no jobs out there. Yes, pharmaceuticals is not the job it used to be and the industry is going to hell in a hand basket. However, nobody wants to leave especially the ones that have over 10 years with the company or are in their late 40s and 50s. You bet they will be cutting again and rumor is in the fall. Nobody is safe especially the 40% that survive because the overall plan is to eliminate another 65% so if you have 800-900 reps left Novartis will have about around 400 by 2013. Words of advice to you my little naive friend. Novartis does not care about you and they only see you as a number. Grow up and start looking for another job or go back to school and get a real degree. I bet your degree is in fashion design. They will not announce anything because there is no set territory and never will be. They are called temporary territories and will never be safe.
Wow, what an angry little man. In my example, I AM one of the ones getting cut who wants to keep a job. My counterpart will probably stay and WILL NOT do overnights. If he gets the job, and there are overnights he will look for a new one immediately but I won't be able to come back when he finds one because I will have taken the severance. I'm hoping they announce new territories soon so he will start looking now!
Anonymous
Guest
Anonymous
Guest
Wow, what an angry little man. In my example, I AM one of the ones getting cut who wants to keep a job. My counterpart will probably stay and WILL NOT do overnights. If he gets the job, and there are overnights he will look for a new one immediately but I won't be able to come back when he finds one because I will have taken the severance. I'm hoping they announce new territories soon so he will start looking now!
Thats not a man... That has to be a woman acting that Bitchy! A woman who got a 1 I bet! I'm w/ you .. What you are saying is the people who really dont want to go usually get laid off. Only to take a severance and not be able to come back when the real losers leave anyway! Don't feel bad about liking your job!
Anonymous
Guest
Anonymous
Guest
Thats not a man... That has to be a woman acting that Bitchy! A woman who got a 1 I bet! I'm w/ you .. What you are saying is the people who really dont want to go usually get laid off. Only to take a severance and not be able to come back when the real losers leave anyway! Don't feel bad about liking your job!
It's not about liking your job. It is about the harsh reality of the industry. For those people who want to stay, great, but you are staying under the guise of security. The above poster is correct. There WILL be another downsizing soon after this one. All primary care products will be generic in the next two years. If you think staying here is the better option, you might want to reevaluate the situation. Don't celebrate if you make the cut, for it will be short lived. Products such as Arcapta, Ilaris and Gilenya are not going to make it unfortunately. Mix that together with the constant product recalls, FDA letters to plants, bad press and no pipeline and you are in for a turbulent ride until the end of the year, at which they will show you the door. Again, it is unfortunate, but not unpredictable. My advice is if you are not cut, to get out ASAP.
Anonymous
Guest
Anonymous
Guest
It's not about liking your job. It is about the harsh reality of the industry. For those people who want to stay, great, but you are staying under the guise of security. The above poster is correct. There WILL be another downsizing soon after this one. All primary care products will be generic in the next two years. If you think staying here is the better option, you might want to reevaluate the situation. Don't celebrate if you make the cut, for it will be short lived. Products such as Arcapta, Ilaris and Gilenya are not going to make it unfortunately. Mix that together with the constant product recalls, FDA letters to plants, bad press and no pipeline and you are in for a turbulent ride until the end of the year, at which they will show you the door. Again, it is unfortunate, but not unpredictable. My advice is if you are not cut, to get out ASAP.
Amen
Anonymous
Guest
Anonymous
Guest
New territories will have 1 or 2 reps per territory -
If you are in a 1 rep territory, and you want to stay, that is the best scenario,
If you are in a 1 rep territory and really want to go, spend your personal days and vacation days wisely and start looking. You could make it to the next severance, but maybe not,
If you are in a 2 rep territory and you hate it here and would have preferred a severence, start looking as above. A 2 rep territory is a 2 person horse race to see who is retained at year's end, but if you really want out, throw the race but not so badly that you are canned before the next severance.
If you are in a 2 rep territory and want to stay, you will work hard, and if your counterpart wants to go, it may be easy to keep your job. Who knows though how they will separate you out on the objective side. Likely you will lead with one product and your counterpart will lead with the other. Values and Behavior should be easy to figure, unless both of you want to stay.....then it may be a miserable dogfight until the next layoff.
By all accounts the industry has died as we know it and now the corpse is rotting. It is starting to stink and even a good severence will get to the point where it is not a strong enough perfume to mask the horrible smell.
If you are in a 1 rep territory, and you want to stay, that is the best scenario,
If you are in a 1 rep territory and really want to go, spend your personal days and vacation days wisely and start looking. You could make it to the next severance, but maybe not,
If you are in a 2 rep territory and you hate it here and would have preferred a severence, start looking as above. A 2 rep territory is a 2 person horse race to see who is retained at year's end, but if you really want out, throw the race but not so badly that you are canned before the next severance.
If you are in a 2 rep territory and want to stay, you will work hard, and if your counterpart wants to go, it may be easy to keep your job. Who knows though how they will separate you out on the objective side. Likely you will lead with one product and your counterpart will lead with the other. Values and Behavior should be easy to figure, unless both of you want to stay.....then it may be a miserable dogfight until the next layoff.
By all accounts the industry has died as we know it and now the corpse is rotting. It is starting to stink and even a good severence will get to the point where it is not a strong enough perfume to mask the horrible smell.
Anonymous
Guest
Anonymous
Guest
Wow, what an angry little man. In my example, I AM one of the ones getting cut who wants to keep a job. My counterpart will probably stay and WILL NOT do overnights. If he gets the job, and there are overnights he will look for a new one immediately but I won't be able to come back when he finds one because I will have taken the severance. I'm hoping they announce new territories soon so he will start looking now!
You must be on of those broads that thinks if you survive that your career is safe for 20 more years. Wake up because they will cut again in the fall. You will be lucky if you last a year. Everyone needs to do some serious self-evalutions on what other alternative to take. Instead of finaglin you position think about alternative careers change that may be of interest to you. Its easy to sit back and think how to save a job but these jobs are going to be gone and you need a plan B. The person above is right and thinking the way you think will land you a perminant career flippin burgers of doing a poll dancing at the local strip joint.
Anonymous
Guest
Anonymous
Guest
Wow, what an angry little man. In my example, I AM one of the ones getting cut who wants to keep a job. My counterpart will probably stay and WILL NOT do overnights. If he gets the job, and there are overnights he will look for a new one immediately but I won't be able to come back when he finds one because I will have taken the severance. I'm hoping they announce new territories soon so he will start looking now!
You sound like someone like I worked with a while ago. A backstabber who thought she knew it all and had it all figured out. Would sell anyone down the river for a favorable in with her boss. Well it didnt work out for her in the end so be careful about salivating for someone else's job. It will absolutely bite you in the end.
Anonymous
Guest
Anonymous
Guest
You sound like someone like I worked with a while ago. A backstabber who thought she knew it all and had it all figured out. Would sell anyone down the river for a favorable in with her boss. Well it didnt work out for her in the end so be careful about salivating for someone else's job. It will absolutely bite you in the end.
You're weird. This girl just wants to keep her job and her counterpart does not. I don't see backstabbing here.
Anonymous
Guest
Anonymous
Guest
When will we know the new district and territory footprints? I know some in my pod won't stay if there are overnights. What is sad is that thiis person will be the one that is kept and then they will find another job as soon as possible leaving the rest of us in the cold. I'm hoping they'll announce the new territories so that those people who don't want them will start looking now for a new position and let the people who want to stay have a better chance!
Yes.